Bernardo Leon Rapoport, Diwakar Davar, Jan-Christoph Simon, Oliver Edgar Bechter, Stéphane Dalle, Yin Wu, Daniel Brungs, Anna Maria Di Giacomo, Hanna Eriksson, Peter Mohr, Rossanna C. Pezo, Egle Ramelyte, Gareth Rivalland, Toshifumi Hoki, Muaz Sadeia, Yayan Zhang, Etah Kurland, Alexander M. Eggermont. "Adaptive phase 2/3 study of EIK1001, a TLR7/8 dual agonist, in combination with pembrolizumab, as first-line therapy in participants with advanced melanoma (TeLuRide-006).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.tps9601